Bookbuilding IPO | ₹30 Cr | Listed at NSE SME | Thu, Jun 18, 2026 - Mon, Jun 22, 2026
Avience Biomedicals IPO is a book build issue of ₹30.24 crores. The issue is entirely a fresh issue of 0.15 crore shares of ₹30.24 crore.
Avience Biomedicals IPO bidding started from Jun 18, 2026 and ended on Jun 22, 2026. The allotment for Avience Biomedicals IPO was finalized on Jun 23, 2026. The shares got listed on the NSE SME on Jun 25, 2026.
Avience Biomedicals IPO is set final issue price at ₹208 per share. The lot size for an application is 600 shares. The minimum amount of investment required by an individual investor (retail) is ₹2,49,600 (1,200 shares) (based on upper price). The minimum lot size for investment in HNI is 3 lots (1,800 shares), amounting to ₹3,74,400.
Fintellectual Corporate Advisors Pvt.Ltd. is the book running lead manager and Skyline Financial Services Pvt.Ltd. is the registrar of the issue. The Market Maker of the company is Asnani Stock Broker Pvt.Ltd.
Refer to Avience Biomedicals IPO RHP for detailed Information.
IPO Open
Thu, Jun 18, 2026
IPO Close
Mon, Jun 22, 2026
Issue Price
₹208 per share
Market Cap (Pre-IPO)
₹114.09 Cr
| IPO Date | 18 to 22 Jun, 2026 |
| Listed on | Thu, Jun 25, 2026 |
| Face Value | ₹10 per share |
| Price Band | ₹196 to ₹208 |
| Issue Price | ₹208 per share |
| Lot Size | 600 Shares |
| Sale Type | Fresh capital only |
| Issue Type | Bookbuilding IPO |
| Listing At | NSE SME |
| Total Issue Size | 14,53,800 shares (agg. up to ₹30 Cr) |
| Reserved for Market Maker | 82,200 shares Asnani Stock Broker Pvt.Ltd. (agg. up to ₹2 Cr) |
| Fresh Issue (Ex Market Maker) | 13,71,600 shares (agg. up to ₹29 Cr) |
| Net Offered to Public | 13,71,600 shares (agg. up to ₹29 Cr) |
| Share Holding Pre Issue | 40,31,256 shares |
| Share Holding Post Issue | 54,85,056 shares |
| NSE Symbol | AVIENCE |
| ISIN | INE0V9I01017 |
Avience Biomedicals IPO comprises a total issue size of 14,53,800 shares. The net offer to the public is 13,71,600 shares, after excluding 82,200 shares allotted on a firm basis. Of the Net offer 6,83,400 (49.83%) are allocated to QIB, 2,07,000 (15.09%) allocated to NII 4,81,200 (35.08%) allocated to RII.
| Investor Category | Shares Offered | % of Net Issue | % of Total Issue |
|---|---|---|---|
| QIB Shares Offered | 6,83,400 | 49.83% | 47.01% |
| − Anchor Investor Shares Offered | 4,09,800 | 28.19% | |
| − QIB (Ex. Anchor) Shares Offered | 2,73,600 | 18.82% | |
| NII (HNI) Shares Offered | 2,07,000 | 15.09% | 14.24% |
| − bNII > ₹10L | 1,38,000 | 9.49% | |
| − sNII < ₹10L | 69,000 | 4.75% | |
| Retail Shares Offered | 4,81,200 | 35.08% | 33.10% |
| Firm Reservations | |||
| Market Maker Shares Offered | 82,200 | 5.65% | |
| Total Shares Offered | 14,53,800 | 100.00% | 100.00% |
Investors can bid for a minimum of 1,200 shares and in multiples of 600 shares thereof.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Individual investors (IND) (Min) | 2 | 1,200 | ₹2,49,600 |
| Individual investors (IND) (Max) | 2 | 1,200 | ₹2,49,600 |
| S-HNI (Min) | 3 | 1,800 | ₹3,74,400 |
| S-HNI (Max) | 8 | 4,800 | ₹9,98,400 |
| B-HNI (Min) | 9 | 5,400 | ₹11,23,200 |
Avience Biomedicals IPO raises ₹8.52 crore from anchor investors. Avience Biomedicals IPO Anchor bid date is June 17, 2026.
📝 Anchor Investors Letter (PDF)
| Bid Date | Wed, Jun 17, 2026 |
| Shares Offered | 4,09,800 |
| Anchor Portion (₹ Cr.) | 8.52 |
| Anchor lock-in period end date for 50% shares (30 Days) | Thu, Jul 23, 2026 |
| Anchor lock-in period end date for remaining shares (90 Days) | Mon, Sep 21, 2026 |
Incorporated in June 2024, Avience Biomedicals Limited is an ISO certified company specializing in manufacturing, supplying, and exporting molecular diagnostic solutions, focusing on biotechnology, genomics, and the IVD industry.
Avience Biomedicals Limited has expanded its product range from IVD rapid test kits to a comprehensive line of medical devices, including serology products and biochemistry analyzers. This demonstrates a commitment to diverse healthcare needs, focusing exclusively on the B2B and B2G markets.
The company's products cater to Pathology Labs, Microbiology Labs, Hospitals, and Research Centers nationwide as well as overseas.
In addition to manufacturing, the Company also act as distributors and traders of medical equipment.
The company's manufacturing unit is situated in Noida, Uttar Pradesh.
The company offers a comprehensive range of diagnostic solutions, including:
As of January 31, 2026, the company had 75 permanent employees and 33 contractual employees
Competitive Strength
| Period Ended | 31 Jan 2026 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Assets | 66.07 | 56.52 | 34.65 |
| Total Income | 41.94 | 45.97 | 24.37 |
| Profit After Tax | 5.74 | 7.23 | 2.14 |
| EBITDA | 10.34 | 11.41 | 4.08 |
| NET Worth | 28.52 | 22.78 | 6.21 |
| Reserves and Surplus | 24.49 | 18.75 | 2.93 |
| Total Borrowing | 26.73 | 22.16 | 15.13 |
| Amount in ₹ Crore | |||
| Company | Issue Type | Issue Size | Issue Price | PE Ratio | Listing Day Close | Listing Gain/Loss % | LTP |
|---|---|---|---|---|---|---|---|
| Anthem Biosciences Ltd. | Mainboard | ₹3,395.00 Cr | ₹570 | 70.62 | ₹730.35 | +28.13% | ₹754.70 (+0.47%) |
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Part finances the capital expenditure towards setting up of a new manufacturing unit at industrial plot no. 70, Sector 28 in the Medical Device Park under the Yamuna Expressway Industrial Development Authority (YEIDA), Gautam Buddha Nagar, Uttar Pradesh | 14.05 |
| 2 | Funding the working capital requirements of the Company | 8.25 |
| 3 | General Corporate Purposes | 3.97 |
| 4 | Public Issue Expenses | 3.97 |
| Total | 30.24 |
| KPI | Jan 31, 206 | Mar 31, 2025 |
|---|---|---|
| ROE | 22.38% | 50.14% |
| ROCE | 16.99% | 24.84% |
| Debt/Equity | 0.94 | 0.97 |
| RoNW | 22.38% | 49.89% |
| PAT Margin | 15.86% | |
| EBITDA Margin | 24.70% | 25.22% |
| Price to Book Value | 2.94 | 3.68 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (₹) | 17.94 | 12.56 |
| P/E (x) | 11.59 | 16.56 |
| Promoter Holding | 87.89% | 64.59% |
| Market Cap | ₹114.09 Cr. |
The Avience Biomedicals IPO is subscribed 385.32 times on June 22, 2026 6:55:00 PM (Day 3). The public issue subscribed 401.36 times in the individual investors category, 196.77 times in the QIB category, and 597.23 times in the NII category. Check Day by Day Subscription Details (Live Status)
| Category | Subscription (x) | Shares Offered | Shares bid for | Total Applications |
|---|---|---|---|---|
| QIB (Ex Anchor) | 196.77 | 2,73,600 | 5,38,37,400 | 172 |
| NII* | 597.23 | 2,07,000 | 12,36,27,600 | 0 |
| bNII (> ₹10L) | 670.18 | 1,38,000 | 9,24,84,600 | |
| sNII (< ₹10L) | 451.35 | 69,000 | 3,11,43,000 | |
| Individual Investor | 401.36 | 4,81,200 | 19,31,32,800 | 1,60,944 |
| Total | 385.32 | 9,61,800 | 37,05,97,800 | 1,92,952 |
Total Applications: 1,92,952
*Market Maker portion is not included to NII/HNI.
| # | Issue Expenses | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Book Running Lead Managers fees including underwriting fees | 0.40 |
| 2 | Underwriting Commission | 1.51 |
| 3 | Fees PayableBrokerage, Selling commission, upload fees and Marketing expenses, Market Maker fees, Processing Fees & Miscellaneous FeesAdvertising, Marketing Expenses and Printing Expenses | 1.64 |
| 4 | Registrars to the issue including NSDL/CDSL and Stock Exchange and other Regulatory Expenses | 0.22 |
| 5 | Legal Advisors, Peer Reviewed Auditor, Practicing Company Secretary & Other Professional costs | 0.13 |
| 6 | Advertising, Marketing Expenses and Printing Expenses | 0.07 |
| Total | 3.97 |
| Price Details | NSE SME |
|---|---|
| Final Issue Price | ₹208.00 |
| Open | ₹395.20 |
| Low | ₹395.20 |
| High | ₹414.95 |
| Last Trade | ₹414.95 |
Lead Manager Reports
Avience Biomedicals IPO is a SME IPO of 14,53,800 equity shares of the face value of ₹10 aggregating up to ₹30 Crores. The issue is priced at ₹208 per share. The minimum order quantity is 600.
The IPO opens on Thu, Jun 18, 2026, and closes on Mon, Jun 22, 2026.
Skyline Financial Services Pvt.Ltd. is the registrar for the IPO. The shares are proposed to be listed on NSE SME.
Zerodha customers can apply online in Avience Biomedicals IPO using UPI as a payment gateway. Zerodha customers can apply in Avience Biomedicals IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Avience Biomedicals IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Avience Biomedicals IPO opens on Thu, Jun 18, 2026 and closes on Mon, Jun 22, 2026.
Avience Biomedicals IPO lot size is 600, and the minimum amount required for application is ₹2,49,600, with 2 lots being the minimum application size.
You can apply in Avience Biomedicals IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Avience Biomedicals IPO will be done on Tuesday, June 23, 2026, and the allotted shares will be credited to your demat account by Wed, Jun 24, 2026. Check the Avience Biomedicals IPO allotment status.
The Avience Biomedicals IPO listing date is on Thu, Jun 25, 2026.
